MXPA02002577A - N3'->p5'-tiofosforamidatos de oligonucleotido. - Google Patents

N3'->p5'-tiofosforamidatos de oligonucleotido.

Info

Publication number: MXPA02002577A
Authority: MX; Mexico
Prior art keywords: oligonucleotides; oligonucleotide; thiophosphoramidates; rarr; synthesis
Prior art date: 1999-09-10

Application number

MXPA02002577A

Other languages

English (en)

Inventor

Sergei Gryaznov

Original Assignee

Geron Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-10

Filing date

2000-09-08

Publication date

2003-10-14

2000-09-08 Application filed by Geron Corp filed Critical Geron Corp

2003-10-14 Publication of MXPA02002577A publication Critical patent/MXPA02002577A/es

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 5
230000015572 biosynthetic process Effects 0.000 title 1
238000003786 synthesis reaction Methods 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 3
230000004570 RNA-binding Effects 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
150000008298 phosphoramidates Chemical class 0.000 abstract 1
230000002194 synthesizing effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6832—Enhancement of hybridisation reaction
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Analytical Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

MXPA02002577A 1999-09-10 2000-09-08 N3'->p5'-tiofosforamidatos de oligonucleotido. MXPA02002577A (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US15320199P	1999-09-10	1999-09-10
US16044499P	1999-10-19	1999-10-19
PCT/US2000/024688 WO2001018015A1 (en)	1999-09-10	2000-09-08	Oligonucleotide n3'→p5' thiophosphoramidates: their synthesis and use

Publications (1)

Publication Number	Publication Date
MXPA02002577A true MXPA02002577A (es)	2003-10-14

Family

ID=26850281

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MXPA02002577A MXPA02002577A (es)	1999-09-10	2000-09-08	N3'->p5'-tiofosforamidatos de oligonucleotido.

Country Status (17)

Country	Link
US (5)	US6608036B1 (es)
EP (2)	EP1992634A1 (es)
JP (2)	JP4267233B2 (es)
KR (2)	KR20070112295A (es)
CN (1)	CN1317291C (es)
AT (1)	ATE391134T1 (es)
AU (2)	AU767646B2 (es)
CA (1)	CA2382521C (es)
CY (1)	CY1108158T1 (es)
DE (1)	DE60038495T2 (es)
DK (1)	DK1210357T3 (es)
ES (1)	ES2302701T3 (es)
HK (1)	HK1049339B (es)
IL (2)	IL148304A0 (es)
MX (1)	MXPA02002577A (es)
PT (1)	PT1210357E (es)
WO (1)	WO2001018015A1 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5523389A (en) *	1992-09-29	1996-06-04	Isis Pharmaceuticals, Inc.	Inhibitors of human immunodeficiency virus
US20030032610A1 (en)	1996-06-03	2003-02-13	Gilchrest Barbara A.	Method to inhibit cell growth using oligonucleotides
NZ513402A (en)	1999-02-12	2003-06-30	Sankyo Co	Novel nucleosides and oligonucleotide analogues
ES2302701T3 (es) *	1999-09-10	2008-08-01	Geron Corporation	N3'-p5' tiofosforamidatos oligonucleotidicos: su sintesis y uso.
EP1274410A2 (en)	2000-03-31	2003-01-15	Trustees Of Boston University	Use of locally applied dna fragments
CA2440322C (en) *	2001-03-23	2014-09-09	Geron Corporation	Oligonucleotide conjugates
US7563618B2 (en) *	2001-03-23	2009-07-21	Geron Corporation	Oligonucleotide conjugates
AU2003244338C1 (en) *	2001-03-23	2008-07-24	Geron Corporation	Oligonucleotide conjugates
DE10159904A1 (de) *	2001-12-06	2003-07-03	Adnagen Ag	Oligonukleotidanordnung, Verfahren zum Nukleotidnachweis sowie Vorrichtung hierfür
WO2004037842A1 (ja) *	2002-10-23	2004-05-06	Sankyo Company, Limited	糖部ｓ型配座の新規人工核酸
EA009442B1 (ru)	2003-06-23	2007-12-28	Герон Корпорейшн	Композиции и способы увеличения активности теломеразы
US9248088B2 (en)	2003-06-25	2016-02-02	Telomerase Activation Sciences, Inc.	Compositions and methods for skin conditioning
NZ545516A (en)	2003-09-09	2009-06-26	Geron Corp	Modified oligonucleotides for telomerase inhibition
WO2005047506A1 (en)	2003-11-04	2005-05-26	Geron Corporation	Rna amidates and thioamidates for rnai
EP1783216A1 (en) *	2004-05-28	2007-05-09	Sankyo Company, Limited	Telomerase-inhibitory ena oligonucleotide
SI3296312T1 (sl)	2004-07-02	2021-08-31	Geron Corporation	Sinteza zaščitenih 3'-amino 5'-fosforamiditnih nukleozidnih monomerov
WO2006063717A2 (en) *	2004-12-16	2006-06-22	Febit Biotech Gmbh	Polymerase-independent analysis of the sequence of polynucleotides
WO2006113426A2 (en) *	2005-04-15	2006-10-26	Geron Corporation	Cancer treatment by combined inhibition of telomerase and tubulin activities
WO2007127163A2 (en)	2006-04-24	2007-11-08	Geron Corporation	Cns-tumor treatment method and composition
SI2898887T1 (sl)	2006-10-30	2019-01-31	Geron Corporation	Kombinirani telomerazni inhibitor in gemcitabin za zdravljenje raka
WO2008094640A2 (en)	2007-01-30	2008-08-07	Geron Corporation	Compounds having anti-adhesive effects on cancer cells
US8011527B2 (en) *	2007-08-10	2011-09-06	Rexam Beverage Can Company	Can end with countersink
EP3330383B1 (en)	2008-10-17	2020-02-12	Geron Corporation	Grn163l for use as telomerase inhibitor in the treatment of cancer
WO2010081082A2 (en) *	2009-01-09	2010-07-15	University College Of Cardiff Consultants Limited	Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
EP2691101A2 (en)	2011-03-31	2014-02-05	Moderna Therapeutics, Inc.	Delivery and formulation of engineered nucleic acids
ES2874774T3 (es)	2011-12-22	2021-11-05	Geron Corp	Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros
US9717685B2 (en)	2012-03-26	2017-08-01	President And Fellows Of Harvard College	Lipid-coated nucleic acid nanostructures of defined shape
US9228189B2 (en)	2012-10-26	2016-01-05	Geron Corporation	C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
CA2887702C (en) *	2012-10-26	2023-08-01	Geron Corporation	C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
US9200327B2 (en)	2012-11-30	2015-12-01	Geron Corporation	Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9375485B2 (en)	2012-12-07	2016-06-28	Geron Corporation	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP2971033B8 (en)	2013-03-15	2019-07-10	ModernaTX, Inc.	Manufacturing methods for production of rna transcripts
EP2983804A4 (en)	2013-03-15	2017-03-01	Moderna Therapeutics, Inc.	Ion exchange purification of mrna
US10077439B2 (en)	2013-03-15	2018-09-18	Modernatx, Inc.	Removal of DNA fragments in mRNA production process
US11377470B2 (en)	2013-03-15	2022-07-05	Modernatx, Inc.	Ribonucleic acid purification
CN103382212B (zh) *	2013-07-06	2016-08-31	中国科学院成都生物研究所	5′位改性嘌呤霉素化合物及其制备方法和用途
RS62529B1 (sr)	2013-07-11	2021-11-30	Modernatx Inc	Kompozicije koje sadrže sintetičke polinukleotide koji kodiraju proteine povezane sa crispr i sintetičke sgrnk i postupci upotrebe
EP3052512A4 (en)	2013-09-30	2017-02-22	Geron Corporation	Phosphorodiamidate backbone linkage for oligonucleotides
WO2015051169A2 (en)	2013-10-02	2015-04-09	Moderna Therapeutics, Inc.	Polynucleotide molecules and uses thereof
EP3065722A4 (en) *	2013-11-08	2017-11-15	Dana-Farber Cancer Institute, Inc.	Nucleic acid nanostructures for in vivo agent delivery
CN111729090A (zh)	2013-12-20	2020-10-02	通用医疗公司	与循环肿瘤细胞相关的方法和测定法
JOP20200257A1 (ar)	2014-05-01	2017-06-16	Geron Corp	تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
US10286086B2 (en)	2014-06-19	2019-05-14	Modernatx, Inc.	Alternative nucleic acid molecules and uses thereof
AU2015289583A1 (en) *	2014-07-16	2017-02-02	Modernatx, Inc.	Chimeric polynucleotides
EP3169335B8 (en)	2014-07-16	2019-10-09	ModernaTX, Inc.	Circular polynucleotides
HRP20201218T1 (hr) *	2015-04-23	2020-12-11	Geron Corporation	Postupci za pripremu polinukleotida uporabom pripravaka multivalentne kationske soli
US11434486B2 (en)	2015-09-17	2022-09-06	Modernatx, Inc.	Polynucleotides containing a morpholino linker
CA2998370A1 (en)	2015-09-17	2017-03-23	Moderna Therapeutics, Inc.	Polynucleotides containing a stabilizing tail region
US12385034B2 (en)	2016-06-24	2025-08-12	Modernatx, Inc.	Methods and apparatus for filtration
EP3318276A1 (en)	2016-11-04	2018-05-09	Janssen Biotech, Inc.	Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
KR102627418B1 (ko)	2016-09-14	2024-01-19	얀센 바이오파마, 인크.	변형된 올리고뉴클레오티드 및 사용 방법
CN109937042B (zh) *	2016-09-20	2023-06-27	科罗拉多州立大学董事会法人团体	使用亚磷酰胺化学法合成主链修饰的吗啉代寡核苷酸和嵌合体
KR20190076050A (ko) *	2016-11-11	2019-07-01	얀센 바이오파마, 인크.	Hbv cccdna용 올리고뉴클레오티드 표적화 방법
WO2018221735A1 (ja) *	2017-06-02	2018-12-06	富田製薬株式会社	新規オリゴヌクレオチド
MA49555A (fr)	2017-07-10	2021-04-28	Geron Corp	Procédé amélioré de préparation d'imetelstat
CA3069010A1 (en)	2017-07-28	2019-01-31	Geron Corporation	Methods of treating myelodysplastic syndrome
JP7478660B2 (ja) *	2017-09-14	2024-05-07	ヤンセンバイオファーマインク．	修飾ヌクレオシドホスホロアミダイト
KR20200131263A (ko) *	2018-03-13	2020-11-23	얀센 파마슈티카 엔.브이.	변형 올리고뉴클레오티드 및 타우병증에서의 사용 방법
US20210198734A1 (en) *	2018-05-25	2021-07-01	New York Institute Of Technology	Direct nucleic acid sequencing method
CN112384521B (zh)	2018-07-05	2024-05-03	安捷伦科技有限公司	用于寡核苷酸合成的双重偶联方法
JP7650798B2 (ja)	2018-11-29	2025-03-25	ジェロン・コーポレーション	骨髄異形成症候群を治療する方法
WO2020210468A1 (en)	2019-04-10	2020-10-15	President And Fellows Of Harvard College	Nucleic acid nanostructures crosslinked with oligolysine
US20230250125A1 (en)	2020-04-01	2023-08-10	Janssen Biopharma, Inc.	Nucleic acid polymers
CN118388567A (zh) *	2024-06-26	2024-07-26	广州表观生物科技有限公司	一种特异性靶向酪氨酸酶、制备方法及其应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4394448A (en)	1978-02-24	1983-07-19	Szoka Jr Francis C	Method of inserting DNA into living cells
US4647529A (en)	1984-06-01	1987-03-03	Rodland Karin D	Hybridization method of detecting nucleic acid sequences with probe containing thionucleotide
US4897355A (en)	1985-01-07	1990-01-30	Syntex (U.S.A.) Inc.	N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5124246A (en)	1987-10-15	1992-06-23	Chiron Corporation	Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5109124A (en)	1988-06-01	1992-04-28	Biogen, Inc.	Nucleic acid probe linked to a label having a terminal cysteine
US5501959A (en)	1989-01-17	1996-03-26	Alamar Biosciences Laboratory, Inc.	Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents
US4958013A (en)	1989-06-06	1990-09-18	Northwestern University	Cholesteryl modified oligonucleotides
US5424186A (en)	1989-06-07	1995-06-13	Affymax Technologies N.V.	Very large scale immobilized polymer synthesis
US5143854A (en)	1989-06-07	1992-09-01	Affymax Technologies N.V.	Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5506212A (en)	1990-01-11	1996-04-09	Isis Pharmaceuticals, Inc.	Oligonucleotides with substantially chirally pure phosphorothioate linkages
IL99120A0 (en) *	1991-08-07	1992-07-15	Yeda Res & Dev	Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5412087A (en)	1992-04-24	1995-05-02	Affymax Technologies N.V.	Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US6017895A (en)	1992-02-10	2000-01-25	Genzyme Corporation	Oligonucleotides possessing zwitterionic moieties
US5489508A (en)	1992-05-13	1996-02-06	University Of Texas System Board Of Regents	Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5645986A (en) *	1992-05-13	1997-07-08	Board Of Reagents, The University Of Texas System	Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5476925A (en)	1993-02-01	1995-12-19	Northwestern University	Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US5654286A (en) *	1993-05-12	1997-08-05	Hostetler; Karl Y.	Nucleotides for topical treatment of psoriasis, and methods for using same
EP0706531A4 (en)	1993-07-02	1998-11-25	Lynx Therapeutics Inc	SYNTHESIS OF BRANCHED NUCLEIC ACIDS
US5637684A (en)	1994-02-23	1997-06-10	Isis Pharmaceuticals, Inc.	Phosphoramidate and phosphorothioamidate oligomeric compounds
AU704549B2 (en) *	1994-03-18	1999-04-29	Lynx Therapeutics, Inc.	Oligonucleotide N3'-P5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties
US5599922A (en)	1994-03-18	1997-02-04	Lynx Therapeutics, Inc.	Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5726297A (en)	1994-03-18	1998-03-10	Lynx Therapeutics, Inc.	Oligodeoxyribonucleotide N3' P5' phosphoramidates
EP1293565A3 (en)	1994-07-07	2004-05-12	Geron Corporation	Mammalian telomerase RNA component
US5958680A (en)	1994-07-07	1999-09-28	Geron Corporation	Mammalian telomerase
US5583016A (en)	1994-07-07	1996-12-10	Geron Corporation	Mammalian telomerase
US5776679A (en)	1994-07-07	1998-07-07	Geron Corporation	Assays for the DNA component of human telomerase
US5972605A (en)	1994-07-07	1999-10-26	Geron Corporation	Assays for regulators of mammalian telomerase expression
US5643890A (en) *	1995-01-31	1997-07-01	The Board Of Regents Of The University Of Nebraska	Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
US5656638A (en)	1995-04-18	1997-08-12	Geron Corporation	Telomerase inhibitors
US5760062A (en)	1995-04-18	1998-06-02	Geron Corporation	Telomerase inhibitors
US5863936A (en)	1995-04-18	1999-01-26	Geron Corporation	Telomerase inhibitors
US6004939A (en)	1995-07-06	1999-12-21	Ctrc Research Foundation Board Of Regents	Methods for modulation and inhibition of telomerase
US5968506A (en) *	1995-08-04	1999-10-19	Geron Corporation	Purified telomerase
US5856096A (en) *	1995-09-20	1999-01-05	Ctrc Research Foundation	Rapid and sensitive assays for detecting and distinguishing between processive and non-processive telomerase activities
US5770613A (en)	1995-09-29	1998-06-23	Geron Corporation	Telomerase inhibitors
US5767278A (en)	1995-10-06	1998-06-16	Geron Corporation	Telomerase inhibitors
US5684143A (en)	1996-02-21	1997-11-04	Lynx Therapeutics, Inc.	Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
WO1997037891A1 (fr)	1996-04-05	1997-10-16	German Viktorovich Demidov	Unite motrice et de transport comportant un module energetique
US6015710A (en) *	1996-04-09	2000-01-18	The University Of Texas System	Modulation of mammalian telomerase by peptide nucleic acids
AU2445997A (en)	1996-04-10	1997-10-29	Lynx Therapeutics, Inc.	Telomerase inhibitors
AU730633B2 (en) *	1996-05-29	2001-03-08	Phillip Belgrader	Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US6444650B1 (en)	1996-10-01	2002-09-03	Geron Corporation	Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6093809A (en)	1996-10-01	2000-07-25	University Technology Corporation	Telomerase
IL129222A0 (en)	1996-10-01	2000-02-17	Geron Corp	Telomerase reverse transcriptase
DE19720151A1 (de) *	1997-05-02	1998-11-05	Max Delbrueck Centrum	Chimäre Oligonucleotide und ihre Verwendung
JPH11228451A (ja) *	1998-02-10	1999-08-24	Kureha Chem Ind Co Ltd	抗癌性増強医薬組成物
ES2302701T3 (es) *	1999-09-10	2008-08-01	Geron Corporation	N3'-p5' tiofosforamidatos oligonucleotidicos: su sintesis y uso.
WO2001074136A2 (en)	2000-03-31	2001-10-11	Geron Corporation	Telomerase inhibitor polynucleotides
US6342358B1 (en)	2000-08-24	2002-01-29	The Regents Of The University Of California	Human telomerase RNA elements
US7354706B2 (en) *	2003-09-09	2008-04-08	The Regents Of The University Of Colorado, A Body Corporate	Use of photopolymerization for amplification and detection of a molecular recognition event

2000
- 2000-09-08 ES ES00961689T patent/ES2302701T3/es not_active Expired - Lifetime
- 2000-09-08 HK HK02108873.3A patent/HK1049339B/en not_active IP Right Cessation
- 2000-09-08 JP JP2001522238A patent/JP4267233B2/ja not_active Expired - Lifetime
- 2000-09-08 AT AT00961689T patent/ATE391134T1/de active
- 2000-09-08 US US09/657,445 patent/US6608036B1/en not_active Expired - Lifetime
- 2000-09-08 MX MXPA02002577A patent/MXPA02002577A/es active IP Right Grant
- 2000-09-08 AU AU73609/00A patent/AU767646B2/en not_active Expired
- 2000-09-08 KR KR1020077024593A patent/KR20070112295A/ko not_active Ceased
- 2000-09-08 CN CNB008127298A patent/CN1317291C/zh not_active Expired - Lifetime
- 2000-09-08 IL IL14830400A patent/IL148304A0/xx active IP Right Grant
- 2000-09-08 KR KR1020027003225A patent/KR100858465B1/ko not_active Expired - Lifetime
- 2000-09-08 DE DE60038495T patent/DE60038495T2/de not_active Expired - Lifetime
- 2000-09-08 CA CA002382521A patent/CA2382521C/en not_active Expired - Lifetime
- 2000-09-08 EP EP08075163A patent/EP1992634A1/en not_active Withdrawn
- 2000-09-08 WO PCT/US2000/024688 patent/WO2001018015A1/en not_active Ceased
- 2000-09-08 PT PT00961689T patent/PT1210357E/pt unknown
- 2000-09-08 EP EP00961689A patent/EP1210357B1/en not_active Expired - Lifetime
- 2000-09-08 DK DK00961689T patent/DK1210357T3/da active
2002
- 2002-02-21 IL IL148304A patent/IL148304A/en unknown
2003
- 2003-06-17 US US10/463,076 patent/US6835826B2/en not_active Expired - Lifetime
- 2003-11-21 AU AU2003262453A patent/AU2003262453A1/en not_active Abandoned
2004
- 2004-10-18 US US10/967,755 patent/US7138383B2/en not_active Expired - Lifetime
2006
- 2006-10-25 US US11/586,993 patent/US20070037770A1/en not_active Abandoned
2008
- 2008-06-26 CY CY20081100672T patent/CY1108158T1/el unknown
- 2008-08-12 JP JP2008208285A patent/JP2009046483A/ja not_active Withdrawn
2014
- 2014-07-09 US US14/327,447 patent/US20140349292A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HK1049339A1 (en)	2003-05-09
CN1317291C (zh)	2007-05-23
CA2382521C (en)	2009-08-25
IL148304A (en)	2007-10-31
KR20020092909A (ko)	2002-12-12
JP2009046483A (ja)	2009-03-05
EP1210357A1 (en)	2002-06-05
KR100858465B1 (ko)	2008-09-16
HK1049339B (en)	2008-06-27
IL148304A0 (en)	2002-09-12
US6608036B1 (en)	2003-08-19
US6835826B2 (en)	2004-12-28
US20140349292A1 (en)	2014-11-27
ES2302701T3 (es)	2008-08-01
EP1210357B1 (en)	2008-04-02
US7138383B2 (en)	2006-11-21
AU2003262453A1 (en)	2003-12-18
DE60038495T2 (de)	2009-04-09
AU7360900A (en)	2001-04-10
EP1992634A1 (en)	2008-11-19
AU767646B2 (en)	2003-11-20
CY1108158T1 (el)	2014-02-12
DK1210357T3 (da)	2008-07-21
PT1210357E (pt)	2008-06-11
US20070037770A1 (en)	2007-02-15
DE60038495D1 (de)	2008-05-15
JP2003513887A (ja)	2003-04-15
WO2001018015A1 (en)	2001-03-15
ATE391134T1 (de)	2008-04-15
JP4267233B2 (ja)	2009-05-27
US20050049408A1 (en)	2005-03-03
US20030212032A1 (en)	2003-11-13
KR20070112295A (ko)	2007-11-22
CA2382521A1 (en)	2001-03-15
CN1373768A (zh)	2002-10-09

Publication	Publication Date	Title
MXPA02002577A (es)	2003-10-14	N3'->p5'-tiofosforamidatos de oligonucleotido.
NO963891D0 (no)	1996-09-17	Oligonukleotid N3'-> P5' fosforamidater: Syntese og forbindelser; hybridiserings- og nukleaseresistanse-egenskaper
CA2223678A1 (en)	1996-10-17	Covalently linked oligonucleotide minor groove binder conjugates
HUT66597A (en)	1994-12-28	Peptide nucleic acids
MXPA01010488A (es)	2003-07-21	Secuencias de acidos nucleicos para proteinas que intervienen en sintesis isoprenoide.
BR9913360A (pt)	2001-07-03	Oxidase de urato
ES2148136T3 (es)	2000-10-16	Nuevos conjugados de proteina-polication.
ATE224908T1 (de)	2002-10-15	Oligomere phosphoramidat- und phosphorthioamidatverbindungen
PT937098E (pt)	2002-12-31	Clonagem recombinatoria in vitro utilizando locais de recombinacao modificados
ATE333261T1 (de)	2006-08-15	Klebstoffzusammensetzung und verfahren zu ihrer herstellung
CA2006008A1 (en)	1990-06-20	Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
DK2351844T3 (da)	2014-09-22	Præparater til forøgelse af transport- og antisense-effektivitet af nukleinsyreanalog i celler
CA2153898A1 (en)	1994-07-21	Method for generating single-stranded dna molecules
DK0804456T3 (da)	2002-12-02	Peptid-nukleinsyre-konjugater
EP1762619A3 (en)	2007-05-09	Multiple-tumor aberrant growth genes
DE3675481D1 (de)	1990-12-13	Verbindungen, enthaltend eine oligonukleotide sequenz, gebunden an eine interkalierungsverbindung und an eine aktivierbare chemische verbindung, ihre synthese und verwendungen als artifizielle sequenzspezifische nuklease.
ATE311402T1 (de)	2005-12-15	Peptidnukleinsäuren mit erhöhter bindungsaffinität, sequenzspezifität und löslichkeit
EP1983052A3 (en)	2009-01-07	Methods of cloning and producing fragment chains with readable information content
CA2382631A1 (en)	2001-03-08	Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids
AU5354301A (en)	2001-10-30	Nucleic acid sequences to proteins involved in tocopherol synthesis
WO1996015240A3 (en)	1996-08-15	Ribozyme analogs
DE69934415D1 (de)	2007-01-25	Neuartiges collectin
EP0777730A4 (en)	1999-10-13	DNA VECTOR FOR BONE-SPECIFIC GENE EXPRESSION
WO2002040631A3 (en)	2003-06-19	Dipeptide seryl-histidine and related oligopeptides cleave dna, protein, and a carboxyl ester

Legal Events

Date	Code	Title	Description
2008-06-09	FG	Grant or registration